Highlights Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.62 ^USD	+2.70%		+1.60%	-9.72%

Apr. 02	Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer	CI
Apr. 02	Voyager Therapeutics, Inc. Announces CFO Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	Feb. 26	CI
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research	Feb. 20	CI
Global markets live: Airbus, Tesla, HSBC, KKR, Pfizer...	Jan. 03
Dpa-AFX Overview: COMPANIES from 03/01/2024 - 15:15	Jan. 03	DP
Novartis: licensing agreement with Voyager Therapeutics	Jan. 03	CF
Novartis Collaborates With Voyager Therapeutics for Gene Therapies	Jan. 02	MT
Voyager Therapeutics Shares Rise Pre-Bell on Gene Therapy Agreement With Novartis Unit	Jan. 02	MT
Voyager Therapeutics Shares Leap Premarket on Novartis Collaboration	Jan. 02	DJ
Novartis signs gene therapy deal with Voyager for $100 mln upfront	Jan. 02	RE
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies	Jan. 02	CI
Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program	Dec. 06	CI
Voyager Therapeutics Swings to Q3 Loss, Collaboration Revenue Drops	Nov. 06	MT
Voyager Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Voyager Therapeutics, Inc. Enters into a First Amendment to its Existing Lease Agreement with LS 75 Hayden, LLC	23-08-16	CI
Voyager Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Sangamo Therapeutics, Inc. and Voyager Therapeutics, Inc. Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease	23-06-29	CI
Voyager Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Voyager Therapeutics Presents New Data for Prospective Alzheimer's, Parkinson's Therapies	23-03-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Highlights

Filters